Biapenem is a 1-beta-methylcarbapenem antibiotic with a wide range of antibacterial activity. Biapenem has a similar antibacterial activity to that of imipenem but is more stable against human renal dehydropeptidase-I and with less neurotoxicity.
Biapenem is a carbapenem antibiotic in which the azetidine and pyrroline rings carry 1-hydroxymethyl and pyrazolo[1,2-a][1,2,4]triazolium-6-ylthio substituents respectively. It has a role as an antibacterial drug. It is a member of carbapenems, a pyrazolotriazole and an organic sulfide.
Biapenem is a parenteral carbapenem antibiotic that has powerful antibacterial activity. The aim of this study is to evaluate the efficacy and safety of biapenem for the treatment of infectious diseases.
Mechanism Of Action
Biapenem is a 1-beta-methylcarbapenem antibiotic with a wide range of antibacterial activity. Biapenem has similar antibacterial activity to that of imipenem but is more stable against human renal dehydropeptidase-I and with less neurotoxicity.
Biapenem is a new parenteral carbapenem antibacterial agent with a broad spectrum of in vitro antibacterial activity encompassing many Gram-negative and Gram-positive aerobic and anaerobic bacteria, including species producing beta-lactamases. Biapenem is more stable than imipenem, meropenem, and panipenem to hydrolysis by human renal dihydro peptidase-I (DHP-I), and therefore does not require the coadministration of a DHP-I inhibitor. After intravenous administration, biapenem is widely distributed and penetrates well into various tissues (e.g. lung tissue) and body fluids (e.g. sputum, pleural effusion, abdominal cavity fluid). In randomized, nonblind, or double-blind clinical trials, biapenem showed good clinical and bacteriological efficacy (similar to that of imipenem/ cilastatin) in the treatment of adult patients with intra-abdominal infections, lower respiratory infections or complicated urinary tract infections. Biapenem is generally well tolerated. The most common adverse events in clinical trials were skin eruptions/rashes, nausea, and diarrhea.
Biapenem is a bacterial cell wall synthesis inhibitor with a broad spectrum of antibiotic activity in vitro. It is stable to hydrolysis by human renal dihydro peptidase I and showed good clinical and microbiological efficacy in the treatment of patients with intra-abdominal, lower respiratory tract, and complicated urinary tract infections. After intravenous administration, it is widely distributed, has linear pharmacokinetics, and is mainly eliminated in the urine with a half-life of approximately 1 h. Biapenem is well tolerated with the most common adverse side effects being skin eruptions/rashes, nausea, and diarrhea.
Indications of Biapenem
- Anti-Infective Agents
- Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection.
Dosage of Biapenem
Due to their expanded spectra, the desire to avoid the generation of resistance, and the fact that, in general, they have poor oral bioavailability, they are administered intravenously in hospital settings for more serious infections.
- Information not available
References
